证券代码：603976 证券简称：正川股份 公告编号：2025-050 债券代码：113624 债券简称：正川转债 重庆正川医药包装材料股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 重庆正川医药包装材料股份有限公司（以下简称"公司"）于 2025 年 8 月 议的通知。会议于 2025 年 8 月 22 日以现场方式在正川永成三楼会议室召开，应 参加监事 3 名，实际参加监事 3 名。 本次会议由监事王志伟先生召集和主持，公司相关人员列席了会议。本次会 议的召集、召开和表决程序均符合《公司法》等法律、行政法规以及《公司章程》 《公司监事会议事规则》的有关规定，会议的召集、召开合法有效。 监事会认为：公司本次计提资产减值准备是按照《企业会计准则》和公司相 关会计政策进行，能够更加真实、公允地反映公司的资产价值和财务状况，决策 程序符合相关法律法规和《公司章程》的有关规定,不存在损害公司及全体股东， 特别是中小股东利益的情况。监事会同意本次计提资产减值准备事项。 表决结果：3 票同意、0 票 ...

Core Viewpoint - The report highlights a significant decline in the company's financial performance for the first half of 2025, with a notable drop in revenue and net profit compared to the same period in the previous year, attributed to market demand fluctuations and pricing pressures in the pharmaceutical packaging materials industry [2][6]. Company Overview and Financial Indicators - Company Name: Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd [1] - Stock Code: 603976 [2] - Total Revenue: CNY 323.67 million, a decrease of 29.75% year-on-year [2] - Total Profit: CNY 15.48 million, a decrease of 69.24% year-on-year [2] - Net Profit Attributable to Shareholders: CNY 14.09 million, a decrease of 68.26% year-on-year [2] - Net Assets: CNY 1.20 billion, a decrease of 1.89% from the previous year [2] Industry and Main Business Situation - The company operates in the pharmaceutical packaging materials industry, which is essential for the pharmaceutical formulation industry and is influenced by the characteristics of downstream pharmaceutical demand [6]. - The industry is experiencing a trend towards higher quality standards, with non-compliant products gradually exiting the market, leading to increased industry concentration [6]. - The aging population and rising health awareness in China are creating significant growth opportunities for the pharmaceutical packaging materials sector [6]. Main Business Analysis - The company specializes in the research, production, and sales of pharmaceutical glass packaging materials, including borosilicate glass vials and sodium-calcium glass vials [4][5]. - The product line includes various types of vials used for injections and oral liquids, which are characterized by excellent physical and chemical properties [4][5]. - The company has established a highly integrated production process, ensuring product quality and meeting the personalized needs of pharmaceutical enterprises [4][8]. Operational Performance Discussion - The company faced challenges due to market demand fluctuations, leading to a decrease in sales volume and revenue [6]. - The company has made significant progress in new business development, particularly in pre-filled syringe technology, and has expanded its overseas market presence [6][7]. - The company has focused on technological innovation, achieving breakthroughs in production efficiency and product quality [6][7]. Competitive Advantages - The company is one of the leading enterprises in the pharmaceutical glass vial industry, with a comprehensive product range and a strong reputation built over nearly 40 years [8][11]. - The company has implemented full automation in its production processes, significantly improving product quality and operational efficiency [10][11]. - The company has a robust research and development framework, holding 51 patents, which supports its competitive edge in the market [10][11].

| 重庆正川医药包装材料股份有限公司2025 | | 年半年度报告摘要 | | | | --- | --- | --- | --- | --- | | 公司代码：603976 | | 公司简称：正川股份 | | | | 重庆正川医药包装材料股份有限公司 | | | | | | 重庆正川医药包装材料股份有限公司2025 | | 年半年度报告摘要 | | | | 第一节 重要提示 | | | | | | www.sse.com.cn 展规划，投资者应当到 | 网站仔细阅读半年度报告全文。 | | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | | 无 | | | | | | 第二节 公司基本情况 | | | | | | 公司股票简况 | | | | | | 股票种类 股票上市交易所 | 股票简称 | | 股票代码 | 变更前股票简 | | 称 | | | | | | A股 上海证券交易所 正川股份 | | | 603976 不适用 | | | 联系人和联系方式 董事会秘书 | | | 证券事务代表 | | | 姓名 费世平 | 顾婷 | | | | | ...

债券代码：113624 债券简称：正川转债 重庆正川医药包装材料股份有限公司 证券代码：603976 证券简称：正川股份 公告编号：2025-051 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》（证监会公告 〔2025〕10 号）和上海证券交易所印发的《上海证券交易所上市公司自律监管 指引第 1 号——规范运作（2025 年 5 月修订）》等相关法律法规的规定，重庆正 川医药包装材料股份有限公司（以下简称"公司"）对 2025 年半年度募集资金 的存放与实际使用情况进行专项报告如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准重庆正川医药包装材料股份有限公 司公开发行可转换公司债券的批复》 （证监许可〔2021〕198 号），公司由主承销 商申万宏源证券承销保荐有限责任公司采用余额包销方式，向社会公众公开发行 可转换公司债券 4,050,000 张，每张面值为人民币 100 元，按面值发行，共计募 集资金 40,5 ...

Group 1 - The company expects to achieve a net profit attributable to shareholders of 10 million to 15 million yuan for the first half of 2025, representing a decrease of 29.3798 million to 34.3798 million yuan compared to the same period last year, which is a year-on-year decline of 66.20% to 77.47% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is also projected to be between 10 million and 15 million yuan, reflecting a similar decrease compared to the previous year [1][2] - The main reasons for the significant decline in performance include fluctuations in market demand from downstream customers, a decrease in product prices, and a reduction in sales volume, leading to a drop in operating revenue and gross profit [2] Group 2 - The company's total profit for the same period last year was 50.3423 million yuan, with a net profit attributable to shareholders of 44.3798 million yuan and a net profit after deducting non-recurring gains and losses of 40.7705 million yuan [2] - The earnings per share for the previous year was 0.29 yuan [2] - The company plans to implement lean management and cost reduction measures in the second half of 2025 to enhance market competitiveness and create value for sustainable development [2]

Core Viewpoint - The recent investment cooperation agreement between China National Pharmaceutical Group (国药集团) and Shandong Pharmaceutical Glass Co., Ltd. (山东药玻) marks a significant shift in the company's ownership structure, potentially enhancing its operational capabilities and market position in the pharmaceutical packaging industry [1][3]. Company Overview - Shandong Pharmaceutical Glass, established in 1970 and listed in June 2002, has developed a comprehensive range of pharmaceutical packaging products, including bottles, stoppers, and caps, becoming a leading manufacturer in the industry [5]. - In Q1 2025, the company reported revenues of 1.242 billion yuan and a net profit attributable to shareholders of 224 million yuan [5]. Investment Details - On June 20, 2023, an investment cooperation agreement was signed, where China National Pharmaceutical Group and its subsidiaries will inject 2.449 billion yuan into Shandong Pharmaceutical Glass's indirect controlling shareholder, Shandong Luzhong Investment Co., Ltd. (鲁中投资), acquiring a 51% stake [1]. - This transaction will change the indirect controlling shareholder from Luzhong Holdings to China National Pharmaceutical Group, with the actual controller shifting from the Yiyuan County Finance Bureau to China National Pharmaceutical Group [1]. Strategic Implications - The partnership aims to enhance the modernization of the industrial system and improve the competitiveness of the pharmaceutical and health industry in Yiyuan County and Zibo City [3]. - The acquisition is seen as a strategic move for China National Pharmaceutical Group to expand its presence in the upstream pharmaceutical supply chain, particularly in the pharmaceutical packaging materials sector [3][5]. Challenges and Opportunities - Despite steady growth, Shandong Pharmaceutical Glass faces challenges such as the need for capital, technology, and management upgrades to further its development [4]. - The collaboration with China National Pharmaceutical Group is expected to provide substantial financial support, access to global marketing networks, and technological advancements, which could significantly enhance the company's competitive edge and contribute to the growth of the local pharmaceutical industry [5].

Group 1 - The core viewpoint of the announcement is that the credit rating for Chongqing Zhengchuan Pharmaceutical Packaging Materials Co., Ltd. remains unchanged at "A+" for both the company and its convertible bonds, with a stable outlook [1][2]. - The previous credit rating was also "A+" for both the company and the convertible bonds, with a stable outlook, indicating consistency in the company's financial health [2]. - The credit rating was conducted by United Credit Rating Co., Ltd., based on a comprehensive analysis of the company's operational and industry conditions [2]. Group 2 - The announcement confirms that the tracking credit rating report is available on the Shanghai Stock Exchange website for further details [2].

Group 1 - The company will stop the conversion of its convertible bonds "Zhengchuan Convertible Bonds" from May 14, 2025, until the equity registration date due to the implementation of the 2024 profit distribution plan [1][3] - The profit distribution plan involves a cash dividend of 2.46 yuan per 10 shares (including tax) to all shareholders, with no capital reserve conversion to share capital or bonus shares [2][3] - The profit distribution plan was approved at the annual general meeting held on April 30, 2025, and details will be disclosed on the Shanghai Stock Exchange and other designated media [2][3] Group 2 - The company will announce the implementation of the profit distribution and the adjustment of the conversion price for the convertible bonds on May 15, 2025 [3] - Holders of "Zhengchuan Convertible Bonds" must convert their bonds before May 13, 2025, to enjoy the benefits of the profit distribution [3]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 无硅油预灌封注射器：采用无硅油润滑系统，解决了传统玻璃预灌封注射器依赖硅油润滑导致的微粒污 染、蛋白质聚集等问题。 低能耗与环保：生产工艺简化，仅需12步左右，相比传统玻璃预灌封注射器的40多个工艺步骤，运行 成本和放行成本更低。 先进制造技术：配备X光检测、对射式光源检测系统等先进制造技术，确保产品质量。 定制化解决方案：基于COC/COP材料的高设计自由度，巴特弗莱可根据客户制剂特性提供个性化解决 方案。 巴特弗莱的首款无硅油高分子鲁尔预灌封产品已于2024年通过相关备案，并率先应用于纳米晶类复杂 注射剂。 公司于2025年第二季度建成第二条全自动生产线，年产能6000万支，进一步巩固其在国内市场的领先 地位。 # 预灌封注射器及市场规模 预灌封注射器是一种预先将药物填充在注射器中的包装系统，通常用于单剂量疫苗或药物的注射。它由生产商 预先填充药物并粘贴针头，使用时无需二次抽药，可直接注射，具有使用方便、剂量准确、减少污染风险等优 点。 全球市场规模 ...